Follicular lymphoma grade III, unspecified, intra-abdominal lymph nodes
ICD-10 C82.23 is a billable code used to indicate a diagnosis of follicular lymphoma grade iii, unspecified, intra-abdominal lymph nodes.
Follicular lymphoma is a type of non-Hodgkin lymphoma characterized by the proliferation of follicle center (germinal center) B-cells. Grade III follicular lymphoma indicates a more aggressive form of the disease, with a higher proliferation index and a tendency to transform into a more aggressive lymphoma. The designation 'unspecified' indicates that the specific characteristics of the lymphoma have not been detailed, which can complicate treatment decisions. Intra-abdominal lymph nodes are commonly involved in this type of lymphoma, leading to symptoms such as abdominal pain, weight loss, and night sweats. The staging of follicular lymphoma is crucial for determining the prognosis and treatment approach, with the Ann Arbor staging system being the most widely used. B-symptoms, which include fever, drenching night sweats, and unexplained weight loss, are significant indicators of disease severity and can influence treatment strategies. Treatment may involve watchful waiting, chemotherapy, immunotherapy, or stem cell transplantation, depending on the stage and symptoms present.
Detailed pathology reports, staging information, and treatment plans must be documented.
Diagnosis of follicular lymphoma, treatment planning, and monitoring of disease progression.
Accurate documentation of B-symptoms and their impact on treatment decisions is crucial.
Histological examination results and grading of lymphoma must be clearly documented.
Biopsy interpretation and grading of lymphomas.
Pathology reports should specify the grade and subtype of lymphoma for accurate coding.
Used when administering chemotherapy for follicular lymphoma.
Document the specific chemotherapy regimen and patient response.
Oncology specialists should ensure that all treatment details are accurately recorded.
Common treatments include chemotherapy regimens such as R-CHOP, immunotherapy, and in some cases, stem cell transplantation. Treatment decisions are based on the patient's overall health, stage of the disease, and presence of B-symptoms.
